Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-dose study of AJM300 (carotegrast methyl) in healthy male adults
jRCT2080224930Phase 1Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing AJM300 with Placebo (2 arms). Primary endpoints: Safety and tolerability of single oral doses of AJM300, Pharmacokinetics of AJM300 and 1 more. Started Oct 2019; status: completed.
02
Drugs
firategrast
Beyond the preview
Go deeper on jRCT2080224930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224930.